Primary objective \- To determine the clinical prognosis by identifying the disease course and severity by treatment with or without eculizumab in patients with aHUS in Korea. Secondary objectives * To determine the clinical prognosis of the disease in all patients with aHUS in Korea. * To determine the clinical prognosis of the disease in patients diagnosed with aHUS prior to the initiation of eculizumab reimbursement system in Korea. * To determine the treatment responses by treatment options in patients with aHUS in Korea. * To identify risk factors that affect mortality in all patients with aHUS in Korea. * To investigate the recurrence and clinical prognosis in patients with aHUS in Korea when eculizumab is discontinued
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinical prognosis (Renal survival) by treatment with or without eculizumab
Timeframe: from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, or date of ESRD diagnosis, whichever came first
Clinical prognosis (Overall survival) by treatment with or without eculizumab
Timeframe: from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, whichever came first